UroToday6d
Integrating New Technologies into Everyday Practice Management "Presentation" - Neal Patel, Mark Thompson, Candice Sonko & Alicia Davis
Integrating New Technologies into Everyday Practice Management "Presentation" - Neal Patel, Mark Thompson, Candice Sonko & Alicia Davis ...
UroToday4d
Spontaneous Resolution of Post-COVID-19-Associated Sacral Neuromodulation Device Dysfunction and Overactive Bladder Symptoms: A Report of Two Cases.
Sacral neuromodulation (SNM) is an effective third-line therapy for overactive bladder (OAB). COVID-19 may have a temporary negative effect on SNM function. We describe two cases of increased sensory ...
UroToday3d
Emerging Technologies to Advance Urologic Care in 2025 - LUGPA 2024 Annual Meeting Presentations
Gautam Jayram discusses key updates in bladder and kidney cancer management. Topics include intermediate-risk bladder cancer, BCG-unresponsive disease, immunotherapy for muscle-invasive bladder cancer ...
UroToday4d
An Anatomical Pathogenesis for Science and Surgery of the Working Group's Recommendations for Female Stress Urinary Incontinence.
To provide a brief anatomical pathogenesis of the Working Group SUI publication recommendations. The anatomical science and surgical practice presented here formed the original basis for the MUS and ...
UroToday4d
Automated real-world data integration improves cancer outcome prediction.
The digitization of health records and growing availability of tumour DNA sequencing provide an opportunity to study the determinants of cancer outcomes with unprecedented richness. Patient data are ...
UroToday4d
Current era HOLEP with MOSES 2.0 technology compared to the gold standard TURP.
Bipolar TURP is regarded as the gold standard for treatment of BPH. Historically, when compared to HOLEP, bTURP has been found to have shorter operative times and is considered more efficient. We ...
UroToday5d
CDK12 Loss Drives Prostate Cancer Progression, Transcription-Replication Conflicts, and Synthetic Lethality with Paralog CDK13 - Beyond the Abstract
The gene encoding transcription-associated cyclin dependent kinase (CDK) 12 is inactivated in a subset of aggressive, castration-resistant prostate cancers. Despite this clinical association, it ...
UroToday5d
Adjuvant therapy for renal cell carcinoma : Relevant patient and tumor factors.
The gold standard in the treatment of localized and locally advanced renal cell carcinoma is surgery. Nevertheless, there is still a risk of tumor relapse. Reducing the risk of recurrence and ...
UroToday5d
Perioperative Complications and In-Hospital Mortality in Paraplegic Radical Cystectomy Patients - Beyond the Abstract
Paraplegic patients represent a challenging-to-treat population. Specifically, due to the bladder function deficiency, they are life-long catheterized. This condition increases the incidence of ...
UroToday6d
Bladder Sparing Options for Muscle-Invasive Bladder Cancer - Beyond the Abstract
Bladder-sparing treatments have gained traction as viable alternatives to radical cystectomy (RC) in the management of muscle-invasive bladder cancer (MIBC). This shift reflects a growing recognition ...
UroToday5d
Perioperative Platform for Muscle-Invasive Bladder Cancer Trials: Designs and Endpoints - Beyond the Abstract
The heterogeneity of muscle-invasive bladder cancer (MIBC) and its unresolved challenges necessitate novel well-designed clinical trial platforms to better understand the biology of each tumor in each ...
UroToday5d
Prostate Cancer Screening: Common Questions and Answers.
Prostate cancer is the most diagnosed noncutaneous malignancy and the second most common cause of cancer death among men in the United States. Risk factors include older age, family history of ...